FDA approves use of iCAD's PowerLook AMP with Philips MicroDose Digital Mammography System

Published on January 8, 2013 at 8:10 AM · No Comments

iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration (FDA) for use of the company's next generation mammography computer-aided detection (CAD) platform, PowerLook Advanced Mammography Platform (AMP)TM, with Digital CAD for Philips' MicroDose Full-Field Digital Mammography System.

“This further broadens our partnerships with leading digital mammography companies and provides radiologists with an innovative combination of assessment tools to improve patient care.”

"We are pleased to provide our customers with a comprehensive mammography solution. This partnership brings together our unique spectral imaging capability enabled through photon counting technology that lets us deliver the best IQ with the lowest dose in the industry and iCAD's industry-leading CAD solution to deliver workflow efficiencies and enhanced patient care," said Kevin Tahmoush, Business Leader for Mammography Solutions of Philips. "Additionally, the modular design of iCAD's PowerLook AMP and the industry-leading CAD product provides our MicroDose customers with unmatched flexibility to choose the products and functionality they need to work more efficiently."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post